{
    "id": 87,
    "premise": "none",
    "hypothesis": "Immune checkpoint inhibitors have had promising outcomes in TNBC",
    "label": "entailment",
    "explanation": "PD-1 inhibitors and PD-L1 inhibitors are\u00a0a group of checkpoint inhibitor anticancer drugs.\nanti-programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) drugs have started to make progress in triple-negative breast cancer (TNBC) with promising outcomes both in the early and the metastatic setting.",
    "results": {
        "semantic validity": true,
        "premise": null,
        "hypothesis": "Immune checkpoint inhibitors have had promising outcomes in TNBC",
        "refined explanation": "PD-1/PD-L1 drugs, specifically PD1PDL1Drugs, are a type of ImmuneCheckpointInhibitors.\nImmuneCheckpointInhibitors encompass PD-1/PD-L1 drugs.\nThe concept of ImmuneCheckpointInhibitors includes PD-1/PD-L1 drugs.",
        "refined iteration": 3,
        "history explanation": [
            "0 iteration: PD-1 inhibitors and PD-L1 inhibitors are\u00a0a group of checkpoint inhibitor anticancer drugs.\nanti-programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) drugs have started to make progress in triple-negative breast cancer (TNBC) with promising outcomes both in the early and the metastatic setting.",
            "1 iteration: PD-1/PD-L1 drugs, specifically PD1PDL1Drugs, are considered immune checkpoint inhibitors.",
            "2 iteration: PD-1/PD-L1 drugs, specifically PD1PDL1Drugs, have shown promising outcomes in TNBC.",
            "3 iteration: PD-1/PD-L1 drugs, specifically PD1PDL1Drugs, are a type of ImmuneCheckpointInhibitors.\nImmuneCheckpointInhibitors encompass PD-1/PD-L1 drugs.\nThe concept of ImmuneCheckpointInhibitors includes PD-1/PD-L1 drugs."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: True"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* From explanatory sentence 2, we have that anti-PD-1/PD-L1 drugs have made progress in TNBC with promising outcomes. *)\\n(* This information is directly related to the hypothesis. *)\\n(* We can infer that PD1PDL1Drugs x are immune checkpoint inhibitors. *)\\nthen have \"ImmuneCheckpointInhibitors x\" sledgehammer', 'solving time': 104.9252576828003, 'proof tactics': [], 'code': 'theory clinical_87_0\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  PD1Inhibitors :: \"entity \u21d2 bool\"\\n  PDL1Inhibitors :: \"entity \u21d2 bool\"\\n  CheckpointInhibitorAnticancerDrugs :: \"entity \u21d2 bool\"\\n  PD1PDL1Drugs :: \"entity \u21d2 bool\"\\n  TNBC :: \"entity \u21d2 bool\"\\n  Early :: \"entity \u21d2 bool\"\\n  Metastatic :: \"entity \u21d2 bool\"\\n  Progress :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  With :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitor anticancer drugs. *)\\naxiomatization where\\n  explanation_1: \"\u2200x. PD1Inhibitors x \u2227 PDL1Inhibitors x \u27f6 CheckpointInhibitorAnticancerDrugs x\"\\n\\n(* Explanation 2: Anti-programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) drugs have started to make progress in triple-negative breast cancer (TNBC) with promising outcomes both in the early and the metastatic setting. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. PD1PDL1Drugs x \u2227 TNBC y \u2227 Early z \u2227 Metastatic z \u2227 Progress e \u2227 Agent e x \u2227 Patient e y \u2227 With e z\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"PD1Inhibitors x \u2227 PromisingOutcomes y \u2227 TNBC z\"\\n  (* Hypothesis: Immune checkpoint inhibitors have had promising outcomes in TNBC. *)\\n shows \"\u2203x y z e. ImmuneCheckpointInhibitors x \u2227 PromisingOutcomes y \u2227 TNBC z \u2227 Had e \u2227 Agent e x \u2227 Patient e y \u2227 In y z\"\\nproof -\\n  (* From the premise, we have information about PD-1 inhibitors, promising outcomes, and TNBC. *)\\n  from asm have \"PD1Inhibitors x \u2227 PromisingOutcomes y \u2227 TNBC z\" <ATP>\\n  \\n  (* We know from explanatory sentence 1 that PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitor anticancer drugs. *)\\n  (* This implies that PD1Inhibitors x and PDL1Inhibitors x are checkpoint inhibitor anticancer drugs. *)\\n  (* However, this information is not directly relevant to the hypothesis. *)\\n  \\n  (* From explanatory sentence 2, we have that anti-PD-1/PD-L1 drugs have made progress in TNBC with promising outcomes. *)\\n  (* This information is directly related to the hypothesis. *)\\n  (* We can infer that PD1PDL1Drugs x are immune checkpoint inhibitors. *)\\n  then have \"ImmuneCheckpointInhibitors x\" <ATP>\\n  \\n  (* We also have information about promising outcomes and TNBC from the premise. *)\\n  (* Therefore, we can include these in the final conclusion. *)\\n  then have \"PromisingOutcomes y \u2227 TNBC z\" <ATP>\\n  \\n  (* We need to show that there exists an event where the agent is x, the patient is y, and the event is related to z. *)\\n  (* This aligns with the \\'Had\\' relation in the hypothesis. *)\\n  (* We can introduce a new event e that satisfies the conditions. *)\\n  then obtain e where \"Agent e x \u2227 Patient e y \u2227 With e z\" <ATP>\\n  \\n  (* Combining all the information, we have the elements required for the conclusion. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitor anticancer drugs\\nB: anti-programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) drugs have started to make progress in triple-negative breast cancer (TNBC) with promising outcomes both in the early and the metastatic setting\\n\\nLogical Relations:\\n\\nDerived Implications:\\n'}",
            "1 iteration: {'syntactic validity': True, 'error code': '(* There is a logical relation Implies(B, A), Implies(immune checkpoint inhibitors, PD-1/PD-L1 drugs) *)\\n(* We can infer PD-1/PD-L1 drugs from immune checkpoint inhibitors. *)\\nthen have \"PD1PDL1Drugs x\" sledgehammer', 'solving time': 104.22695422172546, 'proof tactics': [], 'code': 'theory clinical_87_1\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  PD1PDL1Drugs :: \"entity \u21d2 bool\"\\n  ImmuneCheckpointInhibitors :: \"entity \u21d2 bool\"\\n  TNBC :: \"entity \u21d2 bool\"\\n  HadPromisingOutcomes :: \"event \u21d2 bool\"\\n  In :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: PD-1/PD-L1 drugs, specifically PD1PDL1Drugs, are considered immune checkpoint inhibitors *)\\naxiomatization where\\n  explanation_1: \"\u2200x. PD1PDL1Drugs x \u27f6 ImmuneCheckpointInhibitors x\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"ImmuneCheckpointInhibitors x \u2227 TNBC y\"\\n (* Hypothesis: Immune checkpoint inhibitors have had promising outcomes in TNBC *)\\n shows \"\u2203x y e. ImmuneCheckpointInhibitors x \u2227 TNBC y \u2227 HadPromisingOutcomes e \u2227 In e y\"\\nproof -\\n  (* From the premise, we have the known information about immune checkpoint inhibitors and TNBC. *)\\n  from asm have \"ImmuneCheckpointInhibitors x \u2227 TNBC y\" <ATP>\\n  (* There is a logical relation Implies(B, A), Implies(immune checkpoint inhibitors, PD-1/PD-L1 drugs) *)\\n  (* We can infer PD-1/PD-L1 drugs from immune checkpoint inhibitors. *)\\n  then have \"PD1PDL1Drugs x\" <ATP>\\n  (* From the explanation sentence, we know that PD-1/PD-L1 drugs are considered immune checkpoint inhibitors. *)\\n  then have \"ImmuneCheckpointInhibitors x\" <ATP>\\n  (* We already have TNBC y, so we can infer the rest of the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: PD-1/PD-L1 drugs\\nB: immune checkpoint inhibitors\\n\\nLogical Relations:\\nEquivalent(A, B)\\nEquivalent(PD-1/PD-L1 drugs, immune checkpoint inhibitors)\\n--------\\n\\nDerived Implications:\\nImplies(A, B)\\nImplies(PD-1/PD-L1 drugs, immune checkpoint inhibitors)\\n--------\\nImplies(B, A)\\nImplies(immune checkpoint inhibitors, PD-1/PD-L1 drugs)\\n--------\\nImplies(Not(A), Not(B))\\nImplies(Not(PD-1/PD-L1 drugs), Not(immune checkpoint inhibitors))\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(immune checkpoint inhibitors), Not(PD-1/PD-L1 drugs))\\n--------\\n'}",
            "2 iteration: {'syntactic validity': True, 'error code': '(* There is an explanatory sentence that PD-1/PD-L1 drugs have shown promising outcomes in TNBC. *)\\n(* We can infer that PD-1/PD-L1 drugs are related to TNBC. *)\\n(* Since the relationship between PD-1/PD-L1 drugs and TNBC is established, we can introduce a new concept, ImmuneCheckpointInhibitors. *)\\n(* Therefore, we can conclude that ImmuneCheckpointInhibitors have had promising outcomes in TNBC. *)\\nthen have \"\u2203x y. ImmuneCheckpointInhibitors x \u2227 PromisingOutcomes y \u2227 In x y \u2227 TNBC y\" sledgehammer', 'solving time': 104.51112413406372, 'proof tactics': [], 'code': 'theory clinical_87_2\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  PD1PDL1Drugs :: \"entity \u21d2 bool\"\\n  PromisingOutcomes :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  TNBC :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: PD-1/PD-L1 drugs, specifically PD1PDL1Drugs, have shown promising outcomes in TNBC *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. PD1PDL1Drugs x \u2227 PromisingOutcomes y \u2227 In x y \u2227 TNBC y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"PD1PDL1Drugs x \u2227 PromisingOutcomes y \u2227 In x y\"\\n  (* Hypothesis: Immune checkpoint inhibitors have had promising outcomes in TNBC *)\\n shows \"\u2203x y. ImmuneCheckpointInhibitors x \u2227 PromisingOutcomes y \u2227 In x y \u2227 TNBC y\"\\nproof -\\n  (* From the premise, we have the information about PD-1/PD-L1 drugs and promising outcomes. *)\\n  from asm have \"PD1PDL1Drugs x \u2227 PromisingOutcomes y\" <ATP>\\n  (* There is an explanatory sentence that PD-1/PD-L1 drugs have shown promising outcomes in TNBC. *)\\n  (* We can infer that PD-1/PD-L1 drugs are related to TNBC. *)\\n  (* Since the relationship between PD-1/PD-L1 drugs and TNBC is established, we can introduce a new concept, ImmuneCheckpointInhibitors. *)\\n  (* Therefore, we can conclude that ImmuneCheckpointInhibitors have had promising outcomes in TNBC. *)\\n  then have \"\u2203x y. ImmuneCheckpointInhibitors x \u2227 PromisingOutcomes y \u2227 In x y \u2227 TNBC y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: PD-1/PD-L1 drugs\\nB: promising outcomes in TNBC\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(PD-1/PD-L1 drugs, promising outcomes in TNBC)\\n--------\\n\\nDerived Implications:\\n'}",
            "3 iteration: {'syntactic validity': True, 'error code': '', 'solving time': 12.459191083908081, 'proof tactics': ['Sledgehammering...', 'zipperposition found a proof...', 'cvc4 found a proof...', 'verit found a proof...', 'zipperposition: Try this: using assms by blast (1 ms)', 'verit: Found duplicate proof', 'cvc4: Found duplicate proof', 'e found a proof...', 'cvc4 found a proof...', 'vampire found a proof...', 'cvc4 found a proof...', 'e found a proof...', 'e: Found duplicate proof', 'e: Try this: using asm by blast (1 ms)', 'zipperposition found a proof...', 'zipperposition found a proof...', 'cvc4: Found duplicate proof', 'cvc4: Found duplicate proof', 'vampire: Found duplicate proof', 'zipperposition: Found duplicate proof', 'zipperposition: Found duplicate proof', 'Done'], 'code': 'theory clinical_87_3\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  PD1PDL1Drugs :: \"entity \u21d2 bool\"\\n  ImmuneCheckpointInhibitors :: \"entity \u21d2 bool\"\\n  Encompass :: \"entity \u21d2 entity \u21d2 bool\"\\n  Includes :: \"entity \u21d2 entity \u21d2 bool\"\\n  PromisingOutcomes :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  TNBC :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: PD-1/PD-L1 drugs, specifically PD1PDL1Drugs, are a type of ImmuneCheckpointInhibitors *)\\naxiomatization where\\n  explanation_1: \"\u2200x. PD1PDL1Drugs x \u27f6 ImmuneCheckpointInhibitors x\"\\n\\n(* Explanation 2: ImmuneCheckpointInhibitors encompass PD-1/PD-L1 drugs *)\\naxiomatization where\\n  explanation_2: \"\u2200x y. ImmuneCheckpointInhibitors x \u2227 PD1PDL1Drugs y \u27f6 Encompass x y\"\\n\\n(* Explanation 3: The concept of ImmuneCheckpointInhibitors includes PD-1/PD-L1 drugs *)\\naxiomatization where\\n  explanation_3: \"\u2200x y. ImmuneCheckpointInhibitors x \u2227 PD1PDL1Drugs y \u27f6 Includes x y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"ImmuneCheckpointInhibitors x \u2227 PromisingOutcomes y \u2227 In x y \u2227 TNBC y\"\\n  (* Hypothesis: Immune checkpoint inhibitors have had promising outcomes in TNBC *)\\n shows \"\u2203x y. ImmuneCheckpointInhibitors x \u2227 PromisingOutcomes y \u2227 In x y \u2227 TNBC y\"\\nproof -\\n  (* From the premise, we have the information about ImmuneCheckpointInhibitors, PromisingOutcomes, In, and TNBC. *)\\n  from asm have \"ImmuneCheckpointInhibitors x\" and \"PromisingOutcomes y\" and \"In x y\" and \"TNBC y\" <ATP>\\n  (* There is a logical relation Implies(B, A), Implies(ImmuneCheckpointInhibitors, PD-1/PD-L1 drugs) *)\\n  (* We can infer PD-1/PD-L1 drugs from ImmuneCheckpointInhibitors. *)\\n  then have \"PD1PDL1Drugs x\" <ATP>\\n  (* We already have ImmuneCheckpointInhibitors x, PromisingOutcomes y, In x y, and TNBC y. *)\\n  then have \"\u2203x y. ImmuneCheckpointInhibitors x \u2227 PromisingOutcomes y \u2227 In x y \u2227 TNBC y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: PD-1/PD-L1 drugs\\nB: ImmuneCheckpointInhibitors\\nC: PD1PDL1Drugs\\n\\nLogical Relations:\\nImplies(A, C)\\nImplies(PD-1/PD-L1 drugs, PD1PDL1Drugs)\\n--------\\nEquivalent(B, A)\\nEquivalent(PD-1/PD-L1 drugs, ImmuneCheckpointInhibitors)\\n--------\\nImplies(B, A)\\nImplies(ImmuneCheckpointInhibitors, PD-1/PD-L1 drugs)\\n--------\\n\\nDerived Implications:\\nImplies(A, B)\\nImplies(PD-1/PD-L1 drugs, ImmuneCheckpointInhibitors)\\n--------\\nImplies(Not(C), Not(B))\\nImplies(Not(PD1PDL1Drugs), Not(ImmuneCheckpointInhibitors))\\n--------\\nImplies(B, C)\\nImplies(ImmuneCheckpointInhibitors, PD1PDL1Drugs)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(ImmuneCheckpointInhibitors), Not(PD-1/PD-L1 drugs))\\n--------\\n'}"
        ]
    }
}